Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Cash and Investments Balance: $3.6 million as of December 31, 2024, compared to $8.6 million at December 31, 2023.
Grant Revenue: $5.8 million in 2024, up from $4.9 million in 2023.
Operating Loss: $14.7 million in 2024, compared to $13.3 million in 2023.
Net Loss: $13 million or $0.95 per share in 2024, compared to $13.3 million or $4.24 per share in 2023.
Equity Financing: $15 million in gross proceeds from an underwritten equity financing in early March 2025.
Grant Funding for 2025: Expected to be in the range of $6 to $8 million.
Additional Grant Proceeds: $7.2 million remaining to be received from grants, with $2 million received in Q1 2025.
Department of Defense Grant: Over $2 million remaining from a $3 million award for the Respect pediatric brain cancer trial.
Warning! GuruFocus has detected 1 Warning Sign with PSTV.
Release Date: March 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Plus Therapeutics Inc (NASDAQ:PSTV) successfully completed an underwritten equity financing of $15 million, strengthening its balance sheet and funding key milestones into mid-2026.
The company received FDA orphan designation for its lead drug, Robic, for use in patients with leptomeningeal metastasis (LM) due to lung cancer, adding to previous designations for breast cancer.
Plus Therapeutics Inc (NASDAQ:PSTV) has expanded its senior leadership team with experienced professionals in oncology and diagnostics, enhancing its clinical and commercial capabilities.
The company reported promising clinical data for its lead drug, Robic, in phase one trials, showing a median overall survival of 9 months for LM patients, compared to the historical 4 months.
Plus Therapeutics Inc (NASDAQ:PSTV) is on track to launch its CNI tumor cell enumeration test commercially in 2025, which could significantly increase the total addressable market for Robic.
The company's cash and investments balance decreased from $8.6 million at the end of 2023 to $3.6 million at the end of 2024, indicating a need for careful financial management.
Plus Therapeutics Inc (NASDAQ:PSTV) reported an operating loss of $14.7 million in 2024, up from $13.3 million in 2023, primarily due to increased spending on clinical trials.
The net loss for 2024 was $13 million, which, although slightly lower than 2023, still reflects significant financial challenges.
The company faces uncertainties related to FDA approval processes and the need for further clinical trials to validate its drug's efficacy and safety.
Plus Therapeutics Inc (NASDAQ:PSTV) must navigate complex market access activities, including state licensures and payer agreements, to successfully commercialize its CNI test.
Q: On the CN insight, do you anticipate building up a major sales force or will you look for partners to commercialize this? A: Marc Hedrick, President and CEO: We do not plan to build a major sales force. This is a niche opportunity, and we are starting with academic neuro-oncologists at major oncology centers. There are about 300 neuro-oncologists in the country, and our initial focus will be on this narrow group of thought leaders and major institutions. Over time, we may expand to the broader medical oncology market. Partnering in the US or outside is something we will consider in the future.
Q: The recurrent GBM trial is the most advanced. What must happen to meet the goal of data this year? A: Marc Hedrick, President and CEO: Although superficially GBM is in late-stage phase two, LM could get approved before. We've enrolled over 50 patients, completed phase one, and are over halfway through phase two. The key is adding new sites, and we now have five sites enrolling. We are focused on completing the enrollment of 11 more patients this year.
Q: Can you remind me of the powering assumptions behind the GBM trial? A: Marc Hedrick, President and CEO: The phase two trial's comparator is the standard of care. We've conducted real-world control arms, and patients treated with monotherapy live under 8 months. The trial is powered at 80% with a comparator of about 8 months median overall survival. The trial size is around 100 to 150 patients, and discussions with the FDA about using real-world control data could reduce the number of active patients needed.
Q: On the LM study, you proposed a dose expansion at the 44 milli dose. Is that an additional cohort to the phase one study or part of the phase two study? A: Marc Hedrick, President and CEO: Ideally, the FDA would sign off on a phase 2 trial focused on breast cancer, with 15 patients each for HER2 positive and negative at the 44 milli dose. The phase one dose is a basket trial including various cancer patients. The goal is to sort out patient segmentation by molecular subtype and align with the FDA on endpoints, potentially leading to a phase 2 or phase 23 pivotal design.
Q: Regarding the multi-dose study, would you wait for the first data to come out before initiating a phase two, or would you build that into a phase two? A: Marc Hedrick, President and CEO: We plan to move directly into a phase two or phase 1B. The multi-dose data will be important for performance data and trial design. The phase one data is promising, with long tail survival observed. We aim to pursue a single dose approval quickly, with dose optimization layered on as data becomes available.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Stock Market Today: Dow Jones, S&P 500 Near Highs, Palantir Leads Buys; What Matters For Tesla
The S&P 500 and Nasdaq are rallying toward record highs. Palantir and eToro are in buy areas. Tesla investors should focus on the TSLA chart.
Yahoo
an hour ago
- Yahoo
This AI ETF Could Turn $10,000 Into $40,000 by 2035
It's becoming clearer that artificial intelligence is going to have a meaningful impact on the economy over time. Investors that want diversified exposure to the AI trend should consider this top ETF that has produced a monster 414% total return in the past 10 years. While there continues to be a lot of excitement about AI in the near term, it's important that investors have the patience to focus on the next decade and beyond. 10 stocks we like better than Invesco QQQ Trust › There's no denying it -- artificial intelligence (AI) is likely going to have a profound impact on the world over the long term. Entire industries could be altered. It's no wonder management teams are increasingly focused on ways to better position themselves for long-term success. From an investment perspective, perhaps it's starting to make sense that your portfolio should have some exposure to AI. Luckily, investors don't necessarily need to pick individual stocks if they want to benefit from the trend. There's one top AI exchange-traded fund (ETF) that could turn $10,000 into $40,000 by 2035. Continue reading to learn more about how to supercharge your portfolio for future success. In the last 10 years, the Invesco QQQ Trust (NASDAQ: QQQ) has generated a total return of 414% (as of June 3). This means that a $10,000 investment made in June 2015 would be worth $51,400 today. I don't think anyone in their right mind would complain with that kind of fantastic result. Even better, the expense ratio of 0.20% is a minimal cost to bear for that type of gain. There's no guarantee that past returns will repeat themselves going forward. Let's assume that there is a slowdown. Even so, I wouldn't be surprised if investors who put the same $10,000 in this ETF today see a fourfold gain in the next decade, resulting in a 15% annualized return. There's a lot of talk about how the stock market's current valuation is expensive. But consider that this has been the general narrative for a very long time. Yet that hasn't prevented equity markets from marching higher. The rise of passive investing, ongoing economic expansion, and dominance of tech-driven enterprises have all played a part. I'm fairly confident these trends will continue. The Invesco QQQ Trust can be considered a top AI ETF, even though it contains 100 stocks in total. There is heavy concentration among the top positions, many of which have a meaningful AI focus. The so-called hyperscalers, most notably Amazon, Microsoft, and Alphabet, combined represent 18.9% of the Invesco QQQ Trust's asset base. These dominant companies have leading cloud computing platforms that offer a range of AI tools to their customers. They're collectively planning to spend hundreds of billions of dollars on capital expenditures in 2025 in an effort to bolster their technical infrastructure to better position themselves for an AI future. We can't forget about Nvidia, the biggest beneficiary thus far of the AI boom. It provides the graphics-processing units that power AI data centers, posting unbelievable revenue and profit growth. It's the second-largest holding in the Invesco QQQ Trust. Other top positions are Apple, Meta Platforms, Netflix, and Tesla. There's no doubt that AI has and will keep impacting these businesses in some way as well. Investing correctly means having patience. While the AI craze has definitely made some investors rich in a short period of time, that's the wrong mindset to have. When buying the Invesco QQQ Trust, it's critical to keep the attention on the next decade and beyond. AI has the ability to revolutionize many parts of our economy, and this will all take time to play out. As of this writing, the Invesco QQQ Trust trades 2% off its peak. It might be tempting to wait for a bigger pullback to put money to work. However, I believe this is a flawed approach. It's a smart idea to invest early and often, letting compounding work its magic. Investing in this top AI ETF could work wonders for your portfolio between now and 2035. Before you buy stock in Invesco QQQ Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Neil Patel has positions in Invesco QQQ Trust. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Netflix, Nvidia, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. This AI ETF Could Turn $10,000 Into $40,000 by 2035 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Musk Vs. Trump: Tesla Suffers Record $152B One-Day Crash As CEO Warns Tariffs 'Will Cause A Recession' (UPDATED)
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Tesla Inc. (NASDAQ:TSLA) stock traded down 14.3% to $284.70 on Thursday, the company's second-biggest percentage loss in more than a year and the biggest market cap loss in company history. The decline was caused by an escalated feud between CEO Elon Musk and President Donald Trump. What Happened: Tesla's market cap fell by a company record $152 billion, taking the company out of the $1 trillion market capitalization club. This move comes after Musk publicly criticized Trump's "Big Beautiful Bill." Comments made by Trump in a press interview and by Musk and Trump on social media accounts escalated the battle, with people picking sides in a war of words between two of the world's most influential voices. Trending: Start investing with eToro's CopyTrader — . Musk has been vocal about the projected increase in the national debt from the new spending bill. "Congress is spending America into bankruptcy!" the Tesla CEO tweeted. Trump posted a series of messages on his Truth Social account speaking out against Musk. "I don't mind Elon turning against me, but he should have done so months ago. This is one of the Greatest Bills ever presented to Congress," Trump posted. The president said the bill will put the country "on a path of greatness." Another post had Trump saying that he asked Musk to leave the White House as he was "wearing thin." The president said he removed Musk's EV mandate, which "forced everyone to buy electric cars that nobody else wanted." "And he just went CRAZY!" Trump also suggested that terminating government subsidies and contracts with Musk would be one way to save money. Musk said the president's comments on the EV mandate are "an obvious lie" in a tweet. The Tesla and SpaceX CEO also suggested that he will decommission the Dragon spacecraft in response to Trump's threat on subsidies. The Dragon spacecraft was recently used to bring two stranded astronauts home from the International Space Station. Musk also asked if it was time to create a new political party in America that represents the "80% in the middle." With over 1.1 million votes in, 82% had voted yes, suggesting a third-party option to the Democratic and Republican parties. Escalating the feud further, Musk tweeted that the "really big bomb" is that Trump is in the Epstein files, a reference to the list of people associated with convicted sex offender Jeffrey Epstein. "This is an unfortunate episode from Elon, who is unhappy with the One Big Beautiful Bill because it does not include the policies he wanted. The President is focused on passing this historic piece of legislation and making our country great again, " said White House Press Secretary Karoline Leavitt when asked by Benzinga for comment. Musk also suggested that Trump's tariffs "will cause a recession in the second half" of Stock Falls: Shares of the electric vehicle company suffered their second-largest fall year-to-date on Thursday, narrowly beaten by a 15.4% drop on March 10. That March 10 drop was the largest percentage loss for Tesla shares in five years. The drop came as Musk's role in the White House expanded, and he said he planned to stay involved for another year. The stock had dropped in several sessions around that time amid tariff fears and concerns that Musk's political activism was damaging the Tesla brand. While this marks Tesla's largest market cap drop, it is also shy of the largest percentage drop in 2025 and all time. The largest single-day percentage drop for Tesla stock was on Sept. 8, 2020, when it fell 21.1% after not being selected as a member of the S&P 500 Index. The stock would later be added to the index. Tesla stock fell 19.3% on Jan. 13, 2012 after two key departures were announced, as reported by CNN. The good news for Tesla stock could be its history of rebounds after big drops. After shares fell 15.4% on March 10, 2025, the stock rose 3.8% the following day. After the record 21.1% drop on September 8, 2020, Tesla stock rose 10.9% the next day. Tesla stock has traded between $167.42 and $488.54 over the last year, and it is now down 24.9% year-to-date in 2025. Read Next: Nancy Pelosi Invested $5 Million In An AI Company Last Year — Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000. Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold. Image created using photos from Shutterstock. This article Musk Vs. Trump: Tesla Suffers Record $152B One-Day Crash As CEO Warns Tariffs 'Will Cause A Recession' (UPDATED) originally appeared on
